Wedbush reiterates Outperform rating on Oruka Therapeutics, $165 price target

What happened

Wedbush reiterated an Outperform rating on Oruka Therapeutics stock with a $165.00 price target. That target implies an 82.7% upside from the October 26 close of $90.33, based on the analyst note.

Confirmed

Global impact / market context

A reiterated Outperform rating and $165.00 target signal that Wedbush expects Oruka's psoriasis treatment, ORKA-001, to succeed commercially. That view rests on trial data and planned Phase 3 trial design, which could support the stock and shape how investors position capital in the company.

Analyst inference

The $165.00 target sits 82.7% above the $90.33 close, a wide gap that reflects analyst confidence in upcoming trial results. If that support holds, investors may position for potential gains tied to ORKA-001's clinical and commercial progress, while a setback could compress the implied upside.

Analyst inference

What to watch

1. Wedbush cited positive Phase 2b EVERLAST-B data supporting efficacy seen in the earlier Phase 2a EVERLAST-A trial, reinforcing the annual dosing thesis for psoriasis treatment. Confirmed
2. Management intends to include active comparator arms in Phase 3 trials, which means testing treatments against an existing standard drug rather than a placebo to strengthen credibility and support favorable market uptake. Proposed
3. Investors should watch whether Phase 3 results and commercial uptake justify the $165.00 target, since the implied 82.7% upside depends on ORKA-001 succeeding in trials and the market. Analyst inference

Evidence

• Original source link unavailable